Patents by Inventor Cliff Krein

Cliff Krein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8604076
    Abstract: Pharmaceutical compositions are provided for administration of rotigotine in depot form. Pharmaceutical compositions of the invention can provide therapeutically significant plasma levels of rotigotine over a period of at least 24 hours after administration to a patient. Preferred pharmaceutical compositions of the invention include oily suspensions that contain rotigotine in solid form as well as anhydrous pharmaceutical compositions that comprise rotigotine.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: December 10, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Stephan Rimpler, Sabine Grapatin, Cliff Krein, Markus Thelen
  • Patent number: 7309497
    Abstract: The invention relates to novel pharmaceutical compositions for the systemic administration of pharmacologically active ingredients. The invention relates in particular to an injectable pharmaceutical composition comprising (a) a pharmacologically active ingredient in a solid phase, (b) a vehicle consisting substantially of polyol fatty acid esters with a degree of esterification of over 80%, and (c) a wetting agent consisting substantially of polyol fatty acid esters with a monoester proportion of over 60%. The inventive composition is used for the systemic administration of numerous pharmacologically active ingredients, whereby the ingredients are released from the pharmaceutical composition over a period of at least 12, preferably at least 24 hours.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: December 18, 2007
    Assignee: Schwarz Pharma AG
    Inventors: Stephan Rimpler, Sabine Grapatin, Cliff Krein, Markus Thelen
  • Publication number: 20030180332
    Abstract: The invention relates to novel pharmaceutical compositions for the systematic administration of pharmacologically active ingredients. The invention relates in particular to an injectable pharmaceutical composition comprising (a) a pharmacologically active ingredient in a solid phase, (b) a vehicle consisting substantially of polyol fatty acid esters with a degree of esterification of over 80%, (c) a wetting agent consisting substantially of polyol fatty acid esters with a monoester proportion of over 60%. The inventive composition is used for the systematic administration of numerous pharmacologically active ingredients, whereby the ingredients are released from the pharmaceutical composition over a period of at least 12, preferably at least 24 hours.
    Type: Application
    Filed: February 11, 2003
    Publication date: September 25, 2003
    Inventors: Stephan Rimpler, Sabine Grapatin, Cliff Krein, Markus Thelen
  • Publication number: 20030166709
    Abstract: The invention relates to a pharmaceutical composition for administering the dopamine agonist N-0923 in depot form. The invention makes available for the first time a depot form of N-0923, which achieves a therapeutically significant plasma level over a period of at least 24 hours after administration to a patient. As a result of poor oral bio-availability and the short plasma half-life, N-0923 was previously administered either by an intravenous drip or by transdermal systems. Preferred embodiments of said invention are oily suspensions, containing the active ingredient N-0923 in a solid phase, in addition to anhydrous pharmaceutical preparations of N-0923.
    Type: Application
    Filed: February 11, 2003
    Publication date: September 4, 2003
    Inventors: Stephan Rimpler, Sabine Grapatin, Cliff Krein, Markus Thelen